| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
REVIEW |
1 Prince Henrys Institute of Medical Research, PO Box 5152, Clayton, Victoria, 3168, Australia and 2 Dept of Obstetrics & Gynaecology, Monash University, Clayton, Victoria, 3168, Australia
Correspondence should be addressed to C A White; Email: christine.white{at}phimr.monash.edu.au
| Abstract |
|---|
|
|
|---|
| Principles of microarray analysis |
|---|
|
|
|---|
|
|
| Choice of microarray |
|---|
|
|
|---|
Manufacturers of high-density synthetic oligonucleotide microarrays, such as Affymetrix (Santa Clara, CA, USA; http://www.affymetrix.com), use photolithography and solid-phase DNA synthesis to generate synthetic 25 base polynucleotides (25mers) directly on the glass surface (Lipschutz et al. 1999). Each gene is represented by 11 to 20 different 25 mers, in perfect match or mismatch sequence pairs. Probes can be generated representing a unique part of a gene transcript, enabling discrimination between closely related genes or splice variants and the mismatch sequences provide an internal control for every gene. Longer oligonucleotide (50 to 100 mers) microarrays are also available, which provide even greater hybridisation specificity (Barrett & Kawasaki 2003). Oligo-nucleotide microarrays are hybridised with a single fluorescently labelled sample and gene expression in different samples compared across multiple microarrays. The main disadvantage of these microarrays is their high cost (up to US$800 per slide), so their appeal is likely to increase as they become more economical.
Commercially-available microarrays are printed or synthesised with a particular clone set (reviewed in Bowtell 1999) and these differ in the proportion of known genes and expressed sequence tags (ESTs). Some ESTs correspond to a segment of a known gene, but most represent partially sequenced novel genes. A number of groups including those at Merck, Washington University, the IMAGE (Integrated Analysis of Genomes and their Expression) Consortium and the Cancer Genome Anatomy Project (CGAP) have been responsible for sequencing over one million human ESTs (Bowtell 1999). The online database dbEST (a division of GenBank; http://www.ncbi.nlm.nih.gov/dbEST/index.html) houses all these EST sequences and the automated process known as UniGene assigns overlapping sequences to a single cluster, which may or may not have a known identity (http://www.ncbi.nlm.nih.gov/UniGene/index.html). As the human genome sequence is effectively complete (Venter et al. 2001) it is expected that all ESTs will progressively be assigned an identity. Until then, careful consideration should be given to whether identifying differentially expressed ESTs is a priority in any particular microarray experiment. If not, then using a more tailored array specific to a cellular process or pathway may be more appropriate and cost-effective.
| Experimental design |
|---|
|
|
|---|
A conventional power analysis requires prior knowledge of the variance of individual measurements, the magnitude of the effect to be detected, the acceptable false-positive rate and the desired power of the calculation; that is, the probability of detecting an effect of the specified or greater magnitude (Yang & Speed 2002, Yang et al. 2003, Chen et al. 2004). In a microarray experiment, two of these components are unknown; both the variance of the expression ratio measurements and the magnitude of the effects of interest will be different for every gene on the microarray. To overcome this, power calculations can be performed using the median variance across all of the genes in a previous microarray hybridisation (Yang & Speed 2002).
It is critical that microarray experiments are carefully controlled, particularly when using dual colour fluorescence microarrays in which the endpoint is a ratio of expression between two or more samples. As in any experiment, treatment controls must be carefully incorporated into the study design. To ensure that there is only one source of experimental variation, consistency must also be applied to tissue collection, processing and RNA extraction, as well as the microarray hybridisations. Even with a single variable, such as a differentiation stimulus, it is possible to end up comparing cells or tissues in completely different physiological states. In this situation, differentially expressed genes will likely be the consequence, rather than the cause, of the differences in phenotype. This problem can be minimised by using carefully controlled inducible systems and examining early rather than later time points.
When an experiment involves comparisons across multiple dual colour fluorescence microarrays, there are a number of possible design matrices (Figure 2
). Hybridising an appropriate reference sample to each microarray (Figure 2A
) can provide a consistent control across multiple slides. The ideal reference contains all possible mRNA transcripts present in the experimental samples, so that fluorescence ratio measurements less than zero cannot occur. This is usually achieved by generating a pool of RNA from multiple samples of the tissue or cell type under study. Another approach is to create a reference mixture of all the PCR products spotted on the microarray (Sterrenburg et al. 2002). Although there are some advantages to using a reference sample, it is more precise and economical to make the critical comparisons directly on the same microarray (Figure 2B
; Kerr & Churchill 2001, Churchill 2002). As a reference design requires more complicated statistical analysis, it should only be used for a well-defined purpose. It may also be useful to use a common reference if a large number of experimental samples are to be collected and analysed over a long period of time. A saturated design (Figure 2C
) may be used when an experiment has more than two treatments, and all comparisons are of interest in answering the biological question. The efficiency of time course experiments can be maximised by a loop design (Figure 2D
). Regardless of the design matrix, care should be taken that all pairings are biologically relevant and controlled. For example, pairs could be wild type and knockout littermates, or isolated cells from the same endometrial biopsy with and without treatment.
|
Pooling samples is often considered when RNA is in limited supply, or to minimise the effects of biological variation. In addition, it has been demonstrated that pooling RNA from an increased number of subjects can reduce the number of microarrays required, without any loss of precision (Kendziorski et al. 2003, Peng et al. 2003). Sample pooling should be avoided when it is not possible to accurately synchronise the samples (Sasik et al. 2004). For example, when using pseudopregnant mice on the same day after vaginal plug detection, there is likely to be variation in the time at which mating occurred and therefore in the physiological state of the uterus. In this situation, it is better to maintain sample independence and find common gene expression features at the data analysis stage.
Careful consideration should be given to the use of whole tissue or purified homogeneous cell populations in a microarray study. The advantage of using whole tissue is that there is a greater amount of RNA available for technical replicates and subsequent validation studies (see Data validation below). It is important to consider, however, that tissues contain a range of different cell types. Whole endometrial biopsies, for example, contain luminal and glandular epithelium, non-decidualised and decidualised stroma, endothelial cells, smooth muscle cells and leukocytes. If the cell type of interest makes up a small proportion of the total tissue, whole tissue gene expression data may not be particularly informative. Microarray analysis of purified cells will only reveal genes expressed by those cells, but they will also have been removed from their in vivo microenvironment and cultured under conditions which are likely to alter gene expression. The limitations of both approaches need to be balanced against the aims of the experiment and perhaps additional technologies such as laser capture microdissection (Emmert-Buck et al. 1996) considered. New RNA amplification methods (see Target RNA preparation below) have improved the feasibility of using microdissected tissue for gene expression studies and this approach has the advantage of maintaining close to in vivo cellular context.
The parallel measurement of other biological parameters can be used to assist the interpretation of microarray data. For example, variation in prolactin secretion levels from different preparations of decidualising human endometrial stromal cells may correlate with variations in the expression levels of other genes. When using clinical samples, patient history and tissue histopathology are also critical in the final interpretation of gene expression profiles.
| Target RNA preparation |
|---|
|
|
|---|
Particularly in microarray experiments, it is critical to accurately measure RNA quality and quantity, to minimise variation and therefore improve labelling and hybridisation consistency. The standard UV spectrophotometer is useful for an initial estimate of RNA quality and quantity. Optical density (OD) can be measured at 230, 260 and 280 nm and RNA purity considered acceptable at values of OD260/OD280 1.82.0 and OD230/OD280 < 1.0. Agarose gel electrophoresis may then be used to further confirm RNA integrity. However, other systems such as the RiboGreen Assay (Molecular Probes, Eugene, OR, USA) or the Agilent 2100 Bioanalyser (Agilent Technologies UK Ltd, Cheadle, Cheshire, UK) are more sensitive and accurate. The Agilent Bioanalyser requires only 50500 ng of total RNA and produces a detailed electrophoretogram which will reveal any RNA degradation or genomic DNA contamination.
The amount of RNA required per hybridisation is the greatest limitation to the use of this technology, particularly when the tissue of interest is in limited supply, or when using isolated cell populations. Until very recently, it was recommended that 50200 µg total RNA per sample be used for each hybridisation to generate a sufficient signal (Duggan et al. 1999). However, improved RNA purification, fluorescent labelling methods and hybridisation conditions have reduced this requirement to 510 µg for both glass and nylon membrane arrays. As this amount of RNA may still be difficult to obtain in some systems, a number of different RNA amplification approaches have been developed. The most commonly used method is T7 polymerase in vitro transcription (IVT; van Gelder et al. 1990). While this method can significantly reduce the RNA requirement for each hybridisation, it is also expensive, time-consuming and labour-intensive. In addition, multiple rounds of amplification may be required, which decreases the linearity of the amplification and may result in a cDNA target which is no longer representative of the original sample (Petalidis et al. 2003). Newly developed PCR-based cDNA amplification techniques can decrease the amount of starting total RNA required to 200 ng, while maintaining amplification linearity (Petalidis et al. 2003). This method vastly improves the feasibility of glass microarray studies on clinical samples.
| Microarray hybridisation |
|---|
|
|
|---|
| Image acquisition |
|---|
|
|
|---|
Following image acquisition, the user must align an appropriate grid containing spot identities to the image, as well as identify artefacts of the hybridisation process so that they can be removed from subsequent analyses. As the settings used for background calculation, background thresholds and ratio calculation can greatly influence data quality, the investigator should be aware of the implications of using each of the different methods. Importantly, the methods used for image acquisition can be optimised from slide to slide, but those used for image quantification should be identical for all slides in the experiment (Forster et al. 2003).
| Data analysis |
|---|
|
|
|---|
Graphical displays are useful in determining the overall success of a microarray experiment (Smyth et al. 2003). The red-green image produced during scanning can detect any problems with colour balance, hybridisation, spatial effects, spot quality or artefacts such as scratches and dust. The original red-green image can also be used to check differential expression of a particular gene. Before they are plotted or analysed, the raw intensity data are always log-transformed (log2) to spread the values more evenly across the scale from 0 to 65 535 pixels. If any negative values for red (R) or green (G) foreground intensity have arisen due to high spot background, these will be removed from the analysis on a log scale. Using these log-transformed values, an informative visualisation tool is the MA-plot (Dudoit et al. 2002b). This scatterplot has M-values (R/G ratio log-transformed to M = log2R/G) on the vertical axis and A-values (spot intensity expressed as A = log2
(R x G)) on the horizontal axis. Particularly when using large microarrays with thousands of probes, the majority of genes should not be differentially expressed. An MA-plot of good quality microarray data should therefore have an elongated comet shape centred around M = 0 (i.e. equal red and green intensities over a wide intensity range). As well as helping to identify spot artefacts and intensity-dependent patterns, MA-plots can be used to display the effects of normalisation on the data (Smyth et al. 2003).
Normalisation
Normalisation is essential in microarray experiments to adjust the data for systematic non-biological effects arising from technical variation and measurement error (see Experimental design above). The aim of normalisation is to remove the effect of this noise from the data, while still maintaining the ability to detect significantly differentially expressed genes. When using multiple nylon membrane or other single sample microarrays, each of the arrays must be paired with another and normalised or scaled to its pair (reviewed in Evans et al. 2003). Dual colour fluorescence microarrays require normalisation to account for differences between microarrays, print-tips groups and fluorescent dye channels (reviewed in Smyth & Speed 2003). There is no universally accepted method of microarray data normalisation, and a description and comparison of all available methods is beyond the scope of this review. Overall, the literature supports the use of intensity-dependent normalisation methods, such as print-tip loess (local weighted regression) normalisation (Dudoit et al. 2002b, Yang et al. 2002, Park et al. 2003, Smyth & Speed 2003). This method is capable of removing biases without altering the structure of the data. Essentially, print-tip loess normalisation corrects the M-values (log2R/G ratios) for non-biological spatial and intensity effects.
Statistical analysis
Clustering was one of the first methods used to impose order on microarray data (Eisen et al. 1998). This method involves grouping genes on the basis of similar expression patterns, with the assumption that each cluster of genes is co-ordinately regulated, perhaps as part of the same signaling pathway. Clustering can be useful in assigning potential functions to unidentified genes and ESTs, which can then be tested in further studies. Related methods such as supervised clustering, principle component analysis, self-organising maps and linear discriminant analysis are also widely used to discover patterns of gene expression common to a particular physiological state.
The aim of a microarray experiment is usually to identify differentially expressed genes, with a measure of statistical significance (reviewed in Dudoit et al. 2002b, Cui & Churchill 2003). Most microarray experiments are designed with only one categorical factor (eg. treatment or genotype), so the statistical analysis is based on the paired t-test. Experiments with multiple categorical factors (eg. genotype and time) require methods based on the analysis of variance (ANOVA). Once the data are appropriately normalised, it is common practice to consider a univariate testing problem for each gene and calculate t-statistics (Dudoit et al. 2002b). The t-statistic tests the null hypothesis of equal mean expression levels in the two samples (e.g. treatment and control). Another useful indicator of differential expression is the B-statistic (Lonnstedt & Speed 2002), which is an estimate of the odds that the gene is differentially expressed. The challenge in assigning statistical significance to a differentially expressed gene is that the often thousands of genes on a microarray result in a high level of multiple testing. Determining the false discovery rate is the most powerful method of controlling for multiple testing (Tusher et al. 2001), but this can also be achieved using adjusted P values (Dudoit et al. 2002b). Time course experiments require even more specialised statistical analysis (Cui & Churchill 2003) and should only be conducted if the primary biological question is one of time dependence.
Just as diagnostic MA-plots can be invaluable for visualising trends in raw and normalised data, plots of values obtained during statistical analysis are also useful. Both fold change (difference in gene abundance between two samples) and significance measures can be represented graphically in a volcano plot (Cui & Churchill 2003), with the log odds of differential expression on the vertical axis and the mean M-value (log2R/G ratio) on the horizontal axis. Genes with statistically significant differential expression will appear above a horizontal threshold line and those with large fold changes (up- or downregulated) will lie to the far left or right. Differentially expressed genes identified by the B-statistic will appear in the upper left or right quadrants.
There are many different software packages available for performing normalisation, statistical analysis and visualisation with single and dual sample microarrays. Some of the more widely used packages include Cyber-T (Baldi & Long 2001), SAM (Tusher et al. 2001), BRB-ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools), QVALUE (Storey & Tibshirani 2003) and Focus (Cole et al. 2003). The statistical language R (Ihaka & Gentleman 1996, http://www.r-project.org) has also been used successfully for the analysis of microarray data (Dudoit et al. 2002a) and indeed many of the other packages are based on R commands. Bioconductor (http://www.bioconductor.org) provides a more user-friendly interface for the R statistical language. Although they are often easier for biologists to use, care should be exercised in the choice of commercially available software packages. Some are excellent for data visualisation and normalisation, but cannot assign measures of statistical significance within and across multiple microarrays, or do not handle time course data.
| Data validation |
|---|
|
|
|---|
The first important task for the investigator is to decide which genes to investigate further. From experience, genes displaying a large fold change (>2) and statistical significance are the best candidates for validation. Before embarking on additional studies, it is good practice to review the primary red-green image data to confirm differential expression of these genes, and the spotted DNA sequence may also be checked for correct annotation. Comparing data with that obtained from other microarray studies on the same system can also provide in silico validation and increase confidence in the data set as a whole (Chuaqui et al. 2002).
Quantitative real-time RT-PCR is commonly used to confirm mRNA levels, as it has higher sensitivity and lower RNA requirements than Northern blot. Previous studies have demonstrated that genes with relatively high expression and at least 2-fold regulation are likely to be validated using real-time RT-PCR (Rajeevan et al. 2001). The advantage of Northern blot and RNase protection assay is that they provide a quantitative measure as well as reveal the number and size of transcripts detected by the particular spotted DNA sequence. Quantitative data obtained with microarray and Northern blot are comparable, with Northern blot slightly more sensitive in detecting differential expression compared with microarray (Taniguchi et al. 2001). In complex tissues such as the endometrium, defining the cellular localisation of mRNA expression using in situ hybridisation can provide important functional information. As it is almost impossible to differentiate between primary and secondary gene expression effects in microarray data, further testing may be required to define the molecular interactions occurring.
While mRNA reflects the functional state of the cell, it is the proteins which ultimately carry out the instructions of the genome. Translation of mRNA into protein may be controlled independently of transcription and proteins may undergo post-translational modifications that alter their function. To describe a biological event or system, therefore, gene expression data obtained by microarray analysis must be extended to the study of protein products. Particularly if target RNA has been prepared from whole tissue, characterising the cellular distribution of the corresponding protein by immunostaining or tissue array is critical to understanding the function of a gene. Protein quantification by Western blot or ELISA will indicate whether transcription and translation are co-ordinately regulated.
Defining the functions of differentially expressed genes may be considered the ultimate validation of microarray data. Functional studies may include in vitro experiments using dominant-negative mutants or RNA interference, or in vivo experiments using antisense morpholino oligonucleotides, knockout or conditional knockout technologies. Though the experiments may be carried out some time later, each level of data validation (mRNA, protein and function) should be considered at the microarray experimental design stage, to allow additional controlled samples to be obtained.
| Endometrial gene expression analysis |
|---|
|
|
|---|
A number of endometrial gene expression studies have been discussed in recent reviews (Giudice 2003, 2004, Horcajadas et al. 2004), so rather than providing a detailed description of their findings, the experimental design features of these studies have been summarised in Table 2
. With only three exceptions (Popovici et al. 2000, Martin et al. 2002, Okada et al. 2003), all of these studies included validation of a small number of differentially expressed genes (usually less than 10) by an independent mRNA quantification method (Northern blot, semi-quantitative or quantitative RT-PCR). Less than half also included cellular localisation studies (in situ hybridisation and/or immunohistochemistry).
|
Genes involved in endometrial receptivity and implantation have also been examined using the progesterone receptor antagonist RU486 (Cheon et al. 2002, Catalano et al. 2003, Tynan et al. 2005). As RU486 is known to inhibit implantation in mice and humans, its downstream target genes are likely to be involved in normal implantation, and have been identified in the whole mouse uterus (Cheon et al. 2002), in human endometrial explants (Catalano et al. 2003) and in cynomolgus monkey endometrial biopsies (Tynan et al. 2005). While no genes were found to be regulated by RU486 in all three species, some were identified as downregulated with both RU486 treatment (Cheon et al. 2002) and in post-implantation compared with pre-implantation mouse uterus (Yoshioka et al. 2000). Reese et al.(2001) examined genes involved in mouse implantation using a combined approach of implantation versus interimplantation sites and activated versus delayed implantation. Interestingly, many of the genes regulated in both models were associated with the maternal immune response. Genes found to be regulated in both mouse and human endometrium with the onset of decidualisation and/or receptivity are attractive targets for the manipulation of implantation mechanisms conserved across species.
Microarrays have also been utilised to identify potential markers of endometrial pathologies. Studies exploring differential gene expression in endometriotic lesions versus eutopic endometrium (Eyster et al. 2002, Lebovic et al. 2002, Arimoto et al. 2003) have revealed dysregulation of a number of genes in endometriotic tissue (reviewed in Giudice 2003), which may prove to have functional roles in this disease. Interestingly, a comparison of gene expression in eutopic endometrium from women with and without endometriosis (Kao et al. 2003) has shown that the endometrium of women with endometriosis has an altered transcriptional profile to that of women without the disease. As endometriosis is often associated with infertility, genes with altered expression in endometriosis patients may be involved in endometrial receptivity and embryo implantation (reviewed in Giudice et al. 2002). Similarly, genes found by microarray to be differentially expressed in endometrial tumours compared with normal endometrium (Mutter et al. 2001, Saidi et al. 2004) are likely to provide diagnostic markers and treatment targets in the future (reviewed in Giudice 2003). Another powerful application of microarray technology is the classification of tumour types by their gene expression profiles and a number of studies have successfully utilised this approach in endometrial cancer (Moreno-Bueno et al. 2003, Risinger et al. 2003, Cao et al. 2004, Ferguson et al. 2004, 2005). Molecular classification of tumours using microarray technology has the potential to greatly enhance patient management and improve treatment and prognosis.
| Conclusions |
|---|
|
|
|---|
Despite many recent advances, microarray analysis should not be considered the end-point of an investigation, but rather as a tool to assist in the formulation of hypotheses. With improved microarray quality, standardised data analysis methods and integration with proteomic approaches, gene expression profiling will be an extremely effective tool towards understanding the biology of the reproductive system and in developing diagnostic tests and therapeutic strategies for reproductive abnormalities.
| Acknowledgements |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Ace CI & Okulicz WC 2004 Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase. Reproductive Biology & Endocrinology 2 54.
Arimoto T, Katagiri T, Oda K, Tsunoda T, Yasugi T, Osuga Y, Yoshikawa H, Nishii O, Yano T, Taketani Y & Nakamura Y 2003 Genome-wide cDNA microarray analysis of gene-expression profiles involved in ovarian endometriosis. International Journal of Oncology 22 551560.[Web of Science][Medline]
Baldi P & Long A 2001 A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17 509519.
Barrett JC & Kawasaki ES 2003 Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression. Drug Discovery Today 8 134141.[CrossRef][Web of Science][Medline]
Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phillips SC & Smith SK 2003 Determination of the transcript profile of human endometrium. Molecular Human Reproduction 9 1933.
Bowtell DDL 1999 Options available - from start to finish - for obtaining expression data by microarray. Nature Genetics 21 Suppl 2532.[CrossRef][Web of Science][Medline]
Brar AK, Handwerger S, Kessler CA & Aronow BJ 2001 Gene induction and categorical reprogramming during in vitro human endometrial fibroblast decidualization. Physiological Genomics 7 135148.
Cao QJ, Belbin T, Socci N, Balan R, Prystowsky MB, Childs G & Jones JG 2004 Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. International Journal of Gynecological Pathology 23 321329.[Web of Science][Medline]
Carson DD, Lagow E, Thathiah A, Al-Shami R, Farach-Carson MC, Vernon M, Yuan L, Fritz MA & Lessey B 2002 Changes in gene expression during the early to midluteal (receptive phase) transition in human endometrium detected by high-density microarray screening. Molecular Human Reproduction 8 871879.
Catalano RD, Yanaihara A, Evans AL, Rocha D, Prentice A, Saidi S, Print CG, Charnock-Jones DS, Sharkey AM & Smith SK 2003 The effect of RU486 on the gene expression profile in an endometrial explant model. Molecular Human Reproduction 9 465473.
Chen JJ, Delongchamp RR, Tsai C-A, Hsueh H-M, Sistare F, Thompson KL, Desai VG & Fuscoe JC 2004 Analysis of variance components in gene expression data. Bioinformatics 20 14361446.
Cheon Y-P, Li Q, Xu X, DeMayo FJ, Bagchi IC & Bagchi MK 2002 A genomic approach to identify novel progesterone receptor regulated pathways in the uterus during implantation. Molecular Endocrinology 16 28532871.
Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA & Ahram M et al. 2002 Post-analysis follow-up and validation of microarray experiments. Nature Genetics 32 Suppl 509514.
Churchill GA 2002 Fundamentals of experimental design for cDNA microarrays. Nature Genetics 32 Suppl 490495.
Cole SW, Galic Z & Zack JA 2003 Controlling false negative errors in microarray differential expression analysis: a PRIM approach. Bioinformatics 19 18081816.
Cui X & Churchill GA 2003 Statistical tests for differential expression in cDNA microarray experiments. Genome Biology 4 210.[CrossRef][Medline]
Curtis-Hewitt S, Deroo BJ, Hansen K, Collins J, Grissom S, Afshari CA & Korach KS 2003 Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen. Molecular Endocrinology 17 20702083.
Dominguez F, Avila S, Cervero A, Martin J, Pellicer A, Castrillo JL & Simon C 2003 A combined approach for gene discovery identifies insulin-like growth factor-binding protein-related protein 1 as a new gene implicated in human endometrial receptivity. Journal of Clinical Endocrinology & Metabolism 88 18491857.
Dudoit S, Yang YH & Bolstad B 2002a Using R for the analysis of DNA microarray data. R News 2 2432.
Dudoit S, Yang YH, Callow MJ & Speed TP 2002b Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Statistica Sinica 12 111139.[Web of Science]
Duggan DJ, Bittner M, Chen Y, Meltzer P & Trent JM 1999 Expression profiling using cDNA microarrays. Nature Genetics 21 Suppl 1014.[CrossRef][Web of Science][Medline]
Eisen MB, Spellman PT, Brown PO & Botstein D 1998 Cluster analysis and display of genome-wide expression patterns. PNAS 95 1486314868.
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA & Liotta LA 1996 Laser capture micro-dissection. Science 274 9981001.
Evans AL, Sharkey AS, Saidi SA, Print CG, Catalano RD, Smith SK & Charnock-Jones DS 2003 Generation and use of a tailored gene array to investigate vascular biology. Angiogenesis 6 93104.[CrossRef][Medline]
Eyster KM, Boles AL, Brannian JD & Hansen KA 2002 DNA microarray analysis of gene expression markers of endometriosis. Fertility & Sterility 77 3842.[CrossRef][Web of Science][Medline]
Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR & Boyd J 2004 Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecological Oncology 92 719725.
Ferguson SE, Olshen AB, Viale A, Barakat RR & Boyd J 2005 Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles. Clinical Cancer Research 11 22522257.
Firestein GS & Pisetsky DS 2002 DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology. Arthritis & Rheumatism 46 859861.[CrossRef][Web of Science][Medline]
Forster T, Roy D & Ghazal P 2003 Experiments using microarray technology: limitations and standard operating procedures. Journal of Endocrinology 178 195204.[Abstract]
Fryer RM, Randall J, Yoshida T, Hsaio L-L, Blumenstock J, Jensen KE, Dimofte T, Jensen RV & Gullans SR 2002 Global analysis of gene expression: methods, interpretation, and pitfalls. Experimental Nephrology 10 6474.[CrossRef][Web of Science][Medline]
Giudice LC, Telles TL, Lobo S & Kao LC 2002 The molecular basis for implantation failure in endometriosis: on the road to discovery. Annals of the New York Academy of Sciences 955 252264.[Web of Science][Medline]
Giudice LC 2003 Elucidating endometrial function in the post-genomic era. Human Reproduction Update 9 223235.
Giudice LC 2004 Microarray expression profiling reveals candidate genes for human uterine receptivity. American Journal of Pharmacogenomics 4 299312.
Ho Hong S, Young Nah H, Yoon Lee J, Chan Gye M, Hoon Kim C & Kyoo Kim M 2004 Analysis of estrogen-regulated genes in mouse uterus using cDNA microarray and laser capture microdissection. Journal of Endocrinology 181 157167.[Abstract]
Horcajadas JA, Riesewijk A, Martin J, Cervero A, Mosselman S, Pellicer A & Simon C 2004 Global gene expression profiling of human endometrial receptivity. Journal of Reproductive Immunology 63 4149.[CrossRef][Web of Science][Medline]
Horcajadas JA, Riesewijk A, Polman J, van Os R, Pellicer A, Mosselman S & Simon C 2005 Effect of controlled ovarian hyper-stimulation in IVF on endometrial gene expression profiles. Molecular Human Reproduction 11 195205.
Ihaka R & Gentleman R 1996 R: a language for data analysis and graphics. Journal of Computational & Graphical Statistics 5 299314.[CrossRef]
Ishiwata H, Katsuma S, Kizaki K, Patel OV, Nakano H, Takahashi T, Imai K, Hirasawa A, Shiojima S, Ikawa H, Suzuki Y, Tsujimoto G, Izaike Y, Todoroki J & Hashizume K 2003 Characterization of gene expression profiles in early bovine pregnancy using a custom cDNA microarray. Molecular Reproduction & Development 65 918.
Kao LC, Germeyer A, Tulac S, Lobo S, Yang JP, Taylor RN, Osteen K, Lessey BA & Giudice LC 2003 Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology 144 28702881.
Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, Taylor RN, Lessey BA & Giudice LC 2002 Global gene profiling in human endometrium during the window of implantation. Endocrinology 143 21192138.
Kendziorski CM, Zhang Y, Lan H & Attie AD 2003 The efficiency of pooling mRNA in microarray experiments. Biostatistics 4 465477.[Abstract]
Kerr MK & Churchill GA 2001 Statistical design and the analysis of gene expression microarray data. Genetics Research 77 123128.
Kim JH, Shin DM & Lee YS 2002 Effect of local background intensities in the normalization of cDNA microarray data with a skewed expression profiles. Experimental Molecular Medicine 34 224232.
Knight J 2001 When the chips are down. Nature 410 860861.[CrossRef][Medline]
Kothapalli R, Yoder SJ, Mane S & Loughran TP Jr 2002 Microarray results: how accurate are they? BMC Bioinformatics 3 22.[CrossRef][Medline]
Lebovic DI, Baldocchi RA, Mueller MD & Taylor RN 2002 Altered expression of a cell-cycle suppressor gene, Tob-1, in endometriotic cells by cDNA array analyses. Fertility & Sterility 78 849854.[CrossRef][Web of Science][Medline]
Lipschutz RJ, Fodor SPA, Gingeras TR & Lockhart DJ 1999 High density synthetic oligonucleotide arrays. Nature Genetics 21 Suppl 2024.[CrossRef][Web of Science][Medline]
Lonnstedt I & Speed TP 2002 Replicated microarray data. Statistica Sinica 12 3146.
Matsuzaki S, Canis M, Vaurs-Barriere C, Pouly JL, Boesp-flug-Tanguy O, Penault-Llorca F, Dechelotte P, Dastugue B, Okamura K & Mage G 2004 DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection. Molecular Human Reproduction 10 719728.
Martin J, Dominguez F, Avila S, Castrillo JL, Remohi J, Pellicer A & Simon C 2002 Human endometrial receptivity: gene regulation. Journal of Reproductive Immunology 55 131139.[CrossRef][Web of Science][Medline]
Mirkin S, Nikas G, Hsiu J-G, Diaz J & Oehninger S 2004 Gene expression profiles and structural/functional features of the peri-implantation endometrium in natural and gonadotropin-stimulated cycles. Journal of Clinical Endocrinology & Metabolism 89 57425752.
Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M, Prat J, Matias-Guiu X, Cigudosa JC & Palacios J 2003 Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Research 63 56975702.
Mutter GL, Baak JPA, Fitzgerald JT, Gray R, Neuberg D, Kust GA, Gentleman R, Gullans SR, Wei LJ & Wilcox G 2001 Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecological Oncology 83 177185.
Naciff JM, Jump ML, Torontali SM, Carr GJ, Tiesman JP, Overmann GJ & Daston GP 2002 Gene expression profile induced by 17alpha-ethynyl estradiol, bisphenol A, and genistein in the developing female reproductive system of the rat. Toxicological Sciences 68 184199.
Okada H, Nakajima T, Yoshimura T, Yasuda K & Kanzaki H 2003 Microarray analysis of genes controlled by progesterone in human endometrial stromal cells in vitro. Gynecological Endocrinology 17 271280.[Web of Science][Medline]
Park T, Yi S-G, Kang S-H, Lee S-Y, Lee Y-S & Simon R 2003 Evaluation of normalization methods for microarray data. BMC Bioinformatics 4 33.[CrossRef][Medline]
Peng X, Wood CL, Blalock EM, Chen KC, Landfield PW & Stromberg AJ 2003 Statistical implications of pooling RNA samples for microarray experiments. BMC Bioinformatics 4 26.[CrossRef][Medline]
Petalidis L, Bhattacharyya S, Morris GA, Collins VP, Freeman TC & Lyons PA 2003 Global amplification of mRNA by template-switching PCR: linearity and application to microarray analysis. Nucleic Acids Research 31 e142.
Poggi SH, Goodwin KM, Hill JM, Brenneman DE, Tendi E, Schninelli S & Spong CY 2003 Differential expression of c-fos in a mouse model of fetal alcohol syndrome. American Journal of Obstetrics & Gynecology 189 786789.
Ponnampalam AP, Weston GC, Trajstman AC, Susil B & Rogers PA 2004 Molecular classification of human endometrial cycle stages by transcriptional profiling. Molecular Human Reproduction 10 879893.
Popovici RM, Kao LC & Giudice LC 2000 Discovery of new inducible genes in in vitro decidualized human endometrial stromal cells using microarray technology. Endocrinology 141 35103513.
Punyadeera C, Dassen H, Klomp J, Dunselman G, Kamps R, Dijcks F, Ederveen A, de Goeij A & Groothuis P 2005 Oestrogen-modulated gene expression in the human endometrium. Cellular & Molecular Life Sciences 62 239250.
Rajeevan MS, Vernon SD, Taysavang N & Unger ER 2001 Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. Journal of Molecular Diagnostics 3 2631.
Reese J, Das SK, Paria BC, Lim H, Song H, Matsumoto H, Knudtson KL, DuBois RN & Dey SK 2001 Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation. Journal of Biological Chemistry 276 4413744145.
Riesewijk A, Martin J, van Os R, Horcajadas JA, Polman J, Pellicer A, Mosselman S & Simon C 2003 Gene expression profiling of human endometrial receptivity on days LH + 2 versus LH + 7 by microarray technology. Molecular Human Reproduction 9 253264.
Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, Berchuck A & Barrett JC 2003 Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Research 63 611.
Rockett JC & Hellmann GM 2004 Confirming microarray data - is it really necessary? Genomics 83 541549.[CrossRef][Web of Science][Medline]
Saidi SA, Holland CM, Kreil DP, MacKay DJ, Charnock-Jones DS, Print CG & Smith SK 2004 Independent component analysis of microarray data in the study of endometrial cancer. Oncogene 23 66776683.[CrossRef][Web of Science][Medline]
Sasik R, Woelk CH & Corbeil J 2004 Microarray truths and consequences. Journal of Molecular Endocrinology 33 19.[Abstract]
Schena M, Shalon D, Davis RW & Brown PO 1995 Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 467470.
Smyth GK & Speed T 2003 Normalization of cDNA microarray data. Methods 31 265273.[CrossRef][Web of Science][Medline]
Smyth GK, Yang YH & Speed T 2003 Statistical issues in cDNA microarray data analysis. Methods in Molecular Biology 224 111136.
Stears RL, Martinsky T & Schena M 2003 Trends in microarray analysis. Nature Medicine 9 140145.[CrossRef][Medline]
Sterrenburg E, Turk R, Boer JM, van Ommen GB & den Dunnen JT 2002 A common reference for cDNA microarray hybridizations. Nucleic Acids Research 30 e116.
Storey JD & Tibshirani R 2003 Statistical significance for genome-wide studies. PNAS 100 94409445.
Tan YF, Li FX, Piao YS, Sun XY & Wang YL 2003 Global gene profiling analysis of mouse uterus during the oestrous cycle. Reproduction 126 171182.[Abstract]
Taniguchi M, Miura K, Iwao H & Yamanaka S 2001 Quantitative assessment of DNA microarrays - comparison with Northern blot analyses. Genomics 71 3439.[CrossRef][Web of Science][Medline]
Tierney EP, Tulac S, Huang S-TJ & Giudice LC 2003 Activation of the protein kinase A pathway in human endometrial stromal cells reveals sequential categorical gene regulation. Physiological Genomics 16 4766.
Tusher VG, Tibshirani R & Chu G 2001 Significance analysis of microarrays applied to the ionizing radiation response. PNAS 98 51165121.
Tynan S, Pacia E, Haynes-Johnson D, Lawrence D, DAndrea MR, Guo JZ, Lundeen S & Allan G 2005 The putative tumor suppressor deleted in malignant brain tumors 1 (DMBT1) is an estrogen-regulated gene in rodent and primate endometrial epithelium. Endocrinology 146 10661073.
van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD & Eberwine JH 1990 Amplified RNA synthesized from limited quantities of heterogeneous cDNA. PNAS 87 16631667.
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA & Holt RA et al. 2001 The sequence of the human genome. Science 291 13041351.
Watanabe H, Suzuki A, Kobayashi M, Takahashi E, Itamoto M, Lubahn DB, Handa H & Iguchi T 2003 Analysis of temporal changes in the expression of estrogen-regulated genes in the uterus. Journal of Molecular Endocrinology 30 347358.[Abstract]
Wu X, Pang ST, Sahlin L, Blanck A, Norstedt G & Flores-Morales A 2003 Gene expression profiling of the effects of castration and estrogen treatment in the rat uterus. Biology of Reproduction 69 13081317.
Yanaihara A, Otsuka Y, Iwasaki S, Aida T, Tachikawa T, Irie T & Okai T 2005 Differences in gene expression in the proliferative human endometrium. Fertility & Sterility 83 12061215.
Yang MCK, Yang JJ, McIndoe RA & She JX 2003 Microarray experimental design: power and sample size considerations. Physiological Genomics 16 2428.
Yang YH & Speed T 2002 Design issues for cDNA microarray experiments. Nature Reviews Genetics 3 579588.[CrossRef][Web of Science][Medline]
Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J & Speed TP 2002 Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Research 30 e15.
Yao MW, Lim H, Schust DJ, Choe SE, Farago A, Ding Y, Michaud S, Church GM & Maas RL 2003 Gene expression profiling reveals progesterone-mediated cell cycle and immunoregulatory roles of Hoxa-10 in the preimplantation uterus. Molecular Endocrinology 17 610627.
Yoshioka K, Matsuda F, Takakura K, Noda Y, Imakawa K & Sakai S 2000 Determination of genes involved in the process of implantation: application of GeneChip to scan 6500 genes. Biochemical & Biophysical Research Communications 272 531538.
This article has been cited by other articles:
![]() |
H. W. Ahn, J. L Farmer, F. W Bazer, and T. E Spencer Progesterone and interferon tau-regulated genes in the ovine uterine endometrium: identification of periostin as a potential mediator of conceptus elongation Reproduction, November 1, 2009; 138(5): 813 - 825. [Abstract] [Full Text] [PDF] |
||||
![]() |
S L Rodriguez-Zas, K Schellander, and H A Lewin Biological interpretations of transcriptomic profiles in mammalian oocytes and embryos Reproduction, February 1, 2008; 135(2): 129 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A. Horcajadas, A. Pellicer, and C. Simon Wide genomic analysis of human endometrial receptivity: new times, new opportunities Hum. Reprod. Update, January 1, 2007; 13(1): 77 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. He, W.-Y. Chan, and M. Dym Microarray technology offers a novel tool for the diagnosis and identification of therapeutic targets for male infertility Reproduction, July 1, 2006; 132(1): 11 - 19. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |